Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates.

MLA

Bagan, Jose V., et al. “Collagen Telopeptide (Serum CTX) and Its Relationship with the Size and Number of Lesions in Osteonecrosis of the Jaws in Cancer Patients on Intravenous Bisphosphonates.” Oral Oncology, vol. 44, no. 11, Nov. 2008, pp. 1088–89. EBSCOhost, https://doi.org/10.1016/j.oraloncology.2008.01.012.

APA

Bagan, J. V., Jiménez, Y., Gómez, D., Sirera, R., Poveda, R., & Scully, C. (2008). Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates. Oral Oncology, 44(11), 1088–1089. https://doi.org/10.1016/j.oraloncology.2008.01.012

Chicago

Bagan, Jose V, Yolanda Jiménez, Dolores Gómez, Rafael Sirera, Rafael Poveda, and Crispian Scully. 2008. “Collagen Telopeptide (Serum CTX) and Its Relationship with the Size and Number of Lesions in Osteonecrosis of the Jaws in Cancer Patients on Intravenous Bisphosphonates.” Oral Oncology 44 (11): 1088–89. doi:10.1016/j.oraloncology.2008.01.012.